hiPSC-Derived Cells as Models for Drug Discovery

Area of Science:

• Pharmacology
• Translational Medicine
• Drug Discovery

Background:

• Over 85% of drugs fail during clinical trials.
• Current preclinical animal models often poorly predict human biological responses.
• This inefficiency leads to significant delays and increased costs in drug development.

Discussion:

• The high attrition rate of drug candidates suggests a fundamental disconnect between animal model efficacy and human outcomes.
• Investigating the biological and physiological differences between species is crucial.
• Rethinking the reliance on traditional animal models for predicting human drug response is necessary.

Key Insights:

• Animal models are frequently inadequate predictors of human drug efficacy and safety.
• The limitations of animal models contribute significantly to the high cost and low success rate of pharmaceutical development.
• A paradigm shift in preclinical testing is required to enhance predictive accuracy.

Outlook:

• Developing novel in vitro or in silico models that better mimic human physiology.
• Exploring alternative preclinical testing strategies to improve the success rate of drug candidates.
• Enhancing the translational validity of preclinical research to accelerate the delivery of effective therapies.